Cargando…
Phase I Study of Celecoxib with Concurrent Irinotecan, Cisplatin, and Radiation Therapy for Patients with Unresectable Locally Advanced Non-Small Cell Lung Cancer
Purpose: Preclinical findings suggest that adding targeted therapies to combination radiation-chemotherapy can enhance treatment efficacy; however, this approach may enhance normal tissue toxicity. We investigated the maximum tolerated dose, dose-limiting toxicities, and response rate when the selec...
Autores principales: | Komaki, Ritsuko, Wei, Xiong, Allen, Pamela K., Liao, Zhongxing, Milas, Luka, Cox, James D., O’Reilly, Michael S., Chang, Joe Y., McAleer, Mary Frances, Jeter, Melenda, Blumenschein, George R., Kies, Merrill S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Research Foundation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3355954/ https://www.ncbi.nlm.nih.gov/pubmed/22649768 http://dx.doi.org/10.3389/fonc.2011.00052 |
Ejemplares similares
-
Neoadjuvant irinotecan, cisplatin, and concurrent radiation therapy with celecoxib for patients with locally advanced esophageal cancer
por: Cleary, James M., et al.
Publicado: (2016) -
Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non‐small cell lung cancer
por: Yang, Ju, et al.
Publicado: (2018) -
Dose-finding study of irinotecan and cisplatin plus concurrent radiotherapy for unresectable stage III non-small-cell lung cancer [seecomments]
por: Yokoyama, A., et al.
Publicado: (1998) -
Phase II Study of Irinotecan and Cisplatin Combination Chemotherapy in Metastatic, Unresectable Esophageal Cancer
por: Kim, Miso, et al.
Publicado: (2017) -
Induction cisplatin–irinotecan followed by concurrent cisplatin–irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial
por: Michel, P, et al.
Publicado: (2006)